Psychedelics Archives - Reason Foundation

Psychedelics Policy Newsletter: Trump administration recommendations, Massachusetts loss, and more

Psychedelics Policy Newsletter: Trump administration recommendations, Massachusetts loss, and more

By Gregory Ferenstein

Plus: Government funding for addiction research, veteran’s administration pursues psychedelics, and more.

State psychedelics legalization and policy roundup — December 2024

State psychedelics legalization and policy roundup — December 2024

By Gregory Ferenstein

Psychedelic drug policy recommendations for the incoming Trump administration

Psychedelic drug policy recommendations for the incoming Trump administration

By Geoffrey Lawrence, Leonard Gilroy and Gregory Ferenstein

Psilocybin access would improve mental health care in Massachusetts

Psilocybin access would improve mental health care in Massachusetts

By Gregory Ferenstein

Psychedelics Policy Newsletter: MDMA rejection, advocating for lower state fees in Colorado, and more

Psychedelics Policy Newsletter: MDMA rejection, advocating for lower state fees in Colorado, and more

By Gregory Ferenstein

State psychedelics legalization and policy roundup — September 2024

Commentary by Gregory Ferenstein

Massachusetts Question 4 would legalize and regulate certain psychedelics

Voters' Guide by Leonard Gilroy

Colorado should rethink proposed psychedelic application fees

Testimony by Gregory Ferenstein and Geoffrey Lawrence

Psychedelics Policy Newsletter: A glimpse into Colorado after psychedelics legalization, a gathering of conservative legislators, and more

Psychedelics Policy Newsletter by Gregory Ferenstein

State psychedelics legalization and policy roundup — July 2024

Commentary by Gregory Ferenstein

Colorado could improve regulatory rules regarding psychedelic use

Testimony by Leonard Gilroy, Geoffrey Lawrence, Gregory Ferenstein and Madison Carlino

A glimpse into Colorado’s emerging legal pyschedelics scene

Commentary by Gregory Ferenstein

How the FDA can safely approve a promising but controversial mental health drug

Commentary by Gregory Ferenstein and Geoffrey Lawrence

States can legalize MDMA for pharmaceutical use even if the federal government does not

Commentary by Gregory Ferenstein

Psychedelics Policy Studies

Psychedelic drug policy recommendations for the incoming Trump administration

Backgrounder by Geoffrey Lawrence, Leonard Gilroy and Gregory Ferenstein

Ibogaine treatment for opioid use disorder

Policy Brief by Madison Carlino

Regulated psilocybin access in Arizona would help treat mental health conditions

Backgrounder by Leonard Gilroy and Geoffrey Lawrence

Psychedelics Newsletters

Psychedelics Policy Newsletter: Trump administration recommendations, Massachusetts loss, and more

Psychedelics Policy Newsletter by Gregory Ferenstein

Psychedelics Policy Newsletter: MDMA rejection, advocating for lower state fees in Colorado, and more

Psychedelics Policy Newsletter by Gregory Ferenstein

Sign up for the Psychedelics Policy Newsletter

Email Address(Required)

Comments
This field is for validation purposes and should be left unchanged.

More Psychedelics